A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DM

EARLY_PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 20, 2025

Primary Completion Date

July 24, 2026

Study Completion Date

December 25, 2026

Conditions

Type 1 Diabetes

Interventions

DRUG

RD13-02 cell infusion

CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphami

Trial Locations (1)

Bioheng, Nanjing

All Listed Sponsors

lead

Nanjing Bioheng Biotech Co., Ltd.

INDUSTRY